Guangzhou Baiyunshan Pharmaceutical Holdings Company(DE:GU5)
€1.430.00 (-2.05%)
DE:GU5
Guangzhou Baiyunshan Pharmaceutical Holdings Company financials statements
€1.43
At close:0.00 (-2.05%)
Guangzhou Baiyunshan Pharmaceutical Holdings Company (GU5) Ratios
1 Followers
Guangzhou Baiyunshan Pharmaceutical Holdings Company Ratios
DE:GU5's free cash flow for Q3 2026 was ¥504.39M. For the 2026 fiscal year, DE:GU5's free cash flow was decreased by ¥-239.39M and operating cash flow was ¥743.78M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.57 | 1.48 | 1.55 | 1.53 | 1.64 |
| Quick Ratio | 1.24 | 1.16 | 1.23 | 1.24 | 1.31 |
| Cash Ratio | 0.38 | 0.47 | 0.59 | 0.60 | 0.69 |
| Solvency Ratio | 0.09 | 0.08 | 0.12 | 0.11 | 0.13 |
| Operating Cash Flow Ratio | 0.01 | 0.09 | 0.11 | 0.19 | 0.18 |
| Short-Term Operating Cash Flow Coverage | 0.01 | 0.38 | 0.53 | 0.82 | 0.67 |
| Net Current Asset Value | ¥ 18.14B | ¥ 13.85B | ¥ 14.07B | ¥ 16.04B | ¥ 18.02B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.15 | 0.15 | 0.15 | 0.15 |
| Debt-to-Equity Ratio | 0.55 | 0.34 | 0.34 | 0.36 | 0.34 |
| Debt-to-Capital Ratio | 0.35 | 0.26 | 0.25 | 0.26 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.07 | 0.09 | 0.05 | 0.03 |
| Financial Leverage Ratio | 2.24 | 2.28 | 2.25 | 2.33 | 2.28 |
| Debt Service Coverage Ratio | 0.19 | 0.45 | 0.68 | 0.61 | 0.57 |
| Interest Coverage Ratio | 8.72 | 8.60 | 11.48 | 11.68 | 11.45 |
| Debt to Market Cap | 0.79 | 0.43 | 0.34 | 0.31 | 0.31 |
| Interest Debt Per Share | 12.99 | 7.87 | 7.47 | 7.30 | 6.36 |
| Net Debt to EBITDA | 1.46 | -1.20 | -1.48 | -1.78 | -2.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 16.13% | 16.70% | 18.79% | 18.76% | 19.17% |
| EBIT Margin | 3.89% | 5.37% | 7.36% | 7.74% | 7.45% |
| EBITDA Margin | 5.09% | 6.54% | 8.59% | 8.79% | 8.43% |
| Operating Profit Margin | 4.67% | 4.80% | 6.78% | 7.17% | 6.93% |
| Pretax Profit Margin | 4.75% | 4.81% | 6.77% | 7.12% | 6.84% |
| Net Profit Margin | 3.84% | 3.78% | 5.37% | 5.60% | 5.39% |
| Continuous Operations Profit Margin | 3.94% | 4.00% | 5.64% | 6.01% | 5.75% |
| Net Income Per EBT | 80.84% | 78.60% | 79.36% | 78.65% | 78.76% |
| EBT Per EBIT | 101.68% | 100.31% | 99.80% | 99.39% | 98.68% |
| Return on Assets (ROA) | 3.53% | 3.47% | 5.16% | 5.31% | 5.63% |
| Return on Equity (ROE) | 7.89% | 7.90% | 11.61% | 12.37% | 12.80% |
| Return on Capital Employed (ROCE) | 7.99% | 8.41% | 12.09% | 13.62% | 14.13% |
| Return on Invested Capital (ROIC) | 4.81% | 5.76% | 8.51% | 9.34% | 9.51% |
| Return on Tangible Assets | 3.70% | 3.65% | 5.44% | 5.59% | 5.93% |
| Earnings Yield | 11.53% | 10.20% | 12.43% | 12.01% | 12.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.31 | 3.67 | 3.85 | 3.52 | 3.75 |
| Payables Turnover | 5.20 | 3.83 | 3.91 | 3.84 | 3.79 |
| Inventory Turnover | 4.95 | 4.88 | 5.33 | 5.39 | 5.34 |
| Fixed Asset Turnover | 9.28 | 9.45 | 10.05 | 10.78 | 12.15 |
| Asset Turnover | 0.92 | 0.92 | 0.96 | 0.95 | 1.04 |
| Working Capital Turnover Ratio | 3.77 | 3.89 | 3.83 | 3.52 | 3.57 |
| Cash Conversion Cycle | 113.78 | 79.04 | 69.85 | 76.34 | 69.15 |
| Days of Sales Outstanding | 110.19 | 99.53 | 94.72 | 103.56 | 97.26 |
| Days of Inventory Outstanding | 73.76 | 74.85 | 68.49 | 67.73 | 68.30 |
| Days of Payables Outstanding | 70.17 | 95.35 | 93.36 | 94.95 | 96.40 |
| Operating Cycle | 183.95 | 174.38 | 163.21 | 171.29 | 165.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.16 | 2.12 | 2.52 | 4.31 | 3.49 |
| Free Cash Flow Per Share | -0.59 | 1.42 | 1.52 | 3.45 | 2.72 |
| Dividend Paid and CapEx Coverage Ratio | 0.10 | 1.02 | 1.28 | 2.43 | 2.25 |
| Capital Expenditure Coverage Ratio | 0.21 | 3.05 | 2.52 | 5.06 | 4.52 |
| Operating Cash Flow Coverage Ratio | 0.01 | 0.28 | 0.35 | 0.61 | 0.57 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.05 | 0.05 | 0.10 | 0.08 |
| Free Cash Flow Yield | -3.69% | 8.33% | 7.59% | 17.01% | 14.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 8.70 | 9.82 | 8.05 | 8.32 | 7.99 |
| Price-to-Sales (P/S) Ratio | 0.33 | 0.37 | 0.43 | 0.47 | 0.43 |
| Price-to-Book (P/B) Ratio | 0.68 | 0.77 | 0.93 | 1.03 | 1.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -27.11 | 12.01 | 13.18 | 5.88 | 6.73 |
| Price-to-Operating Cash Flow Ratio | 102.08 | 8.07 | 7.95 | 4.72 | 5.24 |
| Price-to-Earnings Growth (PEG) Ratio | 1.68 | -0.33 | 3.93 | 1.27 | 0.29 |
| Enterprise Value Multiple | 8.00 | 4.47 | 3.55 | 3.53 | 2.97 |
| Enterprise Value | 31.63B | 21.89B | 23.02B | 21.95B | 17.27B |
| EV to EBITDA | 8.00 | 4.47 | 3.55 | 3.53 | 2.97 |
| EV to Sales | 0.41 | 0.29 | 0.30 | 0.31 | 0.25 |
| EV to Free Cash Flow | -33.14 | 9.46 | 9.30 | 3.91 | 3.91 |
| EV to Operating Cash Flow | 124.77 | 6.36 | 5.61 | 3.14 | 3.04 |
| Tangible Book Value Per Share | 22.83 | 20.75 | 20.08 | 18.44 | 17.16 |
| Shareholders’ Equity Per Share | 23.25 | 22.08 | 21.48 | 19.72 | 17.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.17 | 0.17 | 0.16 | 0.16 |
| Revenue Per Share | 47.77 | 46.13 | 46.45 | 43.55 | 42.45 |
| Net Income Per Share | 1.83 | 1.74 | 2.49 | 2.44 | 2.29 |
| Tax Burden | 0.81 | 0.79 | 0.79 | 0.79 | 0.79 |
| Interest Burden | 1.22 | 0.90 | 0.92 | 0.92 | 0.92 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.09 | 1.15 | 0.96 | 1.65 | 1.43 |
Currency in CNY
